The O'Brien Fleming method is a statistical approach used in clinical trials, including those related to cancer research. It is designed to control the Type I error rate when interim analyses are conducted. This method helps determine whether a study should be stopped early for efficacy or futility, thus ensuring that patients are not subjected to ineffective treatments or denied effective ones for too long.
